#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Vascular malformation Acute respiratory distress syndrome Adenomatous polyposis coli Mixed-type liposarcoma Blastic plasmacytoid dendritic cell neoplasia Conjunctivitis allergic Hypersensitivity pneumonitis Chronic myelomonocytic leukaemia Immune-mediated renal disorder Colorectal cancer metastatic Non-Hodgkin's lymphoma unspecified histology aggressive recurrent Myelin oligodendrocyte glycoprotein antibody-associated disease Thrombocytopenia Vulval cancer recurrent Non-Hodgkin's lymphoma unspecified histology indolent More trials…

    Learn about Rare Diseases

    Burkitt’s lymphoma – Basic Information Cerebral arteriovenous malformation haemorrhagic – Trials in Disease Haemophilia A without inhibitors – Basic Information KBG syndrome – Treatment Angelman’s syndrome – Treatment Glomerulonephritis membranous – Treatment Mucous membrane pemphigoid – Basic Information Castleman’s disease Advanced systemic mastocytosis – Basic Information Usher’s syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Vibegron Risperidone USNOFLAST Itolizumab Folic Acid Pazopanib COBALAMIN S227928 IMEROPRUBART Thiamine Nitrate Bp Sorafenib Tosilate PUCOTENLIMAB AZD4512 MORPHINE Mavacamten Methotrexate Sodium Omp10 FIBRIN Paclitaxel Obaluronate Bimekizumab More therapies…

    Learn about Your Condition

    Pancreatic carcinoma Dry eye Head injury Cholestatic pruritus Intermittent claudication Renal injury Primary adrenal insufficiency Bronchopulmonary dysplasia Juvenile idiopathic arthritis Viral myocarditis Osteomyelitis acute Migraine with aura Acute promyelocytic leukaemia Mantle cell lymphoma recurrent Propionic acidaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Pancreatic neuroendocrine tumour

  • A study of belzutifan and lenvatinib for patients with von Hippel-Lindau disease-associated tumors or other specific solid tumors.

    Recruiting

    3 1 1
    Investigated Diseases:
    • Ductal adenocarcinoma of pancreas
    • Oesophageal squamous cell carcinoma
    • Pancreatic neuroendocrine tumour
    Investigated Drugs:
    • Belzutifan
    • Lenvatinib
    Belgium Czechia Denmark Finland France Germany +4

  • A study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Pancreatic neuroendocrine tumour
    Investigated Drugs:
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    • Everolimus
    Austria Belgium France Germany Italy The Netherlands +2

  • Study of 64Cu-DOTATATE and 18F-FDG PET/CT imaging to predict disease progression in patients with neuroendocrine neoplasms

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma metastatic
    • Pancreatic neuroendocrine tumour metastatic
    • Small intestine neuroendocrine tumour
    Investigated Drugs:
    • Dotatate
    • Fludeoxyglucose (18F)
    • Copper (64Cu) Chloride
    Denmark

  • Study of Combined Imaging with Hyperpolarized [1-13C]Pyruvate and Fludeoxyglucose (18F) for Cancer Detection in Patients with Breast Cancer, Neuroendocrine Tumors, Lymphomas, or Sarcomas

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma metastatic
    • Pancreatic neuroendocrine tumour metastatic
    • Gastroenteropancreatic neuroendocrine tumour disease
    Investigated Drugs:
    • Fludeoxyglucose (18F)
    • Pyruvic Acid
    Denmark

  • Study on Continuing Somatostatin Analogues with Sunitinib, Octreotide, and Lutetium (177Lu) Oxodotreotide for Patients with Neuroendocrine Tumors

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastroenteropancreatic neuroendocrine tumour disease
    • Neuroendocrine tumour
    • Pancreatic neuroendocrine tumour
    Investigated Drugs:
    • Lutetium (177Lu) Oxodotreotide
    • Lanreotide
    • Octreotide
    Belgium The Netherlands

  • Randomized phase III adjuvant capecitabine plus temozolomide versus surveillance in patients with resected stage I‑III pancreatic neuroendocrine tumors

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Pancreatic neuroendocrine tumour
    Investigated Drugs:
    • Temozolomide
    • Capecitabine
    France
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!